Archimedes makes progress with novel drug delivery technology
This article was originally published in Scrip
Executive Summary
Archimedes Pharma has strengthened its portfolio with positive results in Phase I proof-of-concept studies of two intranasal development projects. The development adds to the strong outlook already created by its lead investigational product NasalFent (fentanyl citrate), which is due to be filed for approval in the first half of this year.